Farha Deceus

Farha Deceus

Auto-generated profile, based on publicly available information

Farha Deceus

Mayo Clinic Alix School of Medicine, Scottsdale, AZ, United States

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 March 2024 in JAACAP Open
Verified
Journal Article
Open access
HUHayrunnisa Unlu
Hayrunnisa Unlu
AYAsmaa Yehia
Asmaa Yehia
SESherif El-Gayar
Sherif El-Gayar
AHAmogh Havanur
Amogh Havanur
FDFarha Deceus
Farha Deceus
OAOsama Ali Abulseoud
Osama Ali Abulseoud
Despite the high prevalence of underage drinking, little is known about alcohol withdrawal syndrome (AWS) in adolescents and young adults. The aim of this study is to characterize AWS in this population. We conducted a retrospective chart review of all hospital admissions with the Clinical Institute Withdrawal Assessment of Alcohol Scale, Revised (CIWA-Ar) protocol at Mayo Clinic between June 2019 and June 2022. We identified a total of 10,220 patients with 16,338 hospital admissions where CIWA-Ar protocol was implemented. Within this cohort, 130 patients (70 male and 60 female; 1.3% of all patients) with 148 admissions (0.9% of all admissions) were under 21 years of age. A total of 44% of patients (n = 65) presented with suicidal ideations, and 26% (n = 40) had suicide attempts. In all, 22 (n = 33) required admission to the intensive care unit. The median length of stay in the intensive care unit was 32.8 hours. The median peak CIWA-Ar score was 9 (minimum-maximum = 4-39, interquartile range = 7), and the median time from hospital admission to peak CIWA-Ar score was 9.4 hours (minimum-maximum = 0.1-126, interquartile range = 20.2). A total of 40% of patients (n = 59) received benzodiazepines, whereas 20% (n = 31) required antipsychotics. Three patients (2%) developed delirium tremens, and 5 episodes of alcohol withdrawal seizures (3.4%) were observed. No deaths were reported during hospitalization. However, over the subsequent follow-up period from 2019 to 2023, the all-cause post-hospitalization mortality rate was 3% (n = 4) within 1.6 (±0.6) years. These data suggest that adolescents and young adults presenting for treatment of AWS are at risk for morbidity and mortality due to suicidality and withdrawal complications such as withdrawal seizures and delirium tremens. Further studies should evaluate the underlying social and neurobiological predictors of vulnerability and resilience in this age group.

12 December 2025 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
PLP Connor Lentz
P Connor Lentz
EDEmily Dorairaj
Emily Dorairaj
PVPranav Vasu
Pranav Vasu
IWIsabella Wagner
Isabella Wagner
JJJaxson Jeffery
Jaxson Jeffery
SDSyril K. Dorairaj
Syril K. Dorairaj
Background: Mobile visual acuity (VA) apps have emerged as valuable tools in both clinical and home settings, particularly in the context of expanding teleophthalmology. Despite the growing number of apps available to measure visual acuity, studies evaluating their overall quality, functionality, and clinical relevance are limited. Objective: This study aimed to systematically evaluate the quality and features of mobile VA apps available on iOS and Android platforms using the clinically validated Mobile App Rating Scale (MARS). Methods: A comprehensive search of the Google Play Store and Apple App Store was conducted between January 2024 and March 2024 using standardized search terms. Eligible apps included free, English-language VA testing tools not requiring external devices. App characteristics and features were extracted. Each app was independently evaluated by 2 trained reviewers using MARS, which rates engagement, functionality, aesthetics, information quality, and subjective quality on a 5-point scale. Results: Of the 725 apps initially identified, 44 met the inclusion criteria, with 23 from the Google Play Store and 21 from the Apple App Store. The most common VA test optotypes used were Tumbling E (n=21; 48%), Snellen Chart (18/44; 41%), and Landolt C (n=14; 32%). Common supplemental features included color vision testing (n=20; 46%), astigmatism tests (n=13; 30%), Amsler grid (n=13; 30%), and contrast testing (n=12; 28%). The average MARS scores were comparable across platforms: 3.04 (SD 0.80) for Android and 3.02 (SD 0.84) for iOS. Functionality received the highest ratings (mean 3.65, SD 0.75 for Android; mean 3.71, SD 0.82 for iOS), while subjective quality received the lowest (mean 2.09, SD 1.01 for Android; mean 2.21, SD 1.01 for iOS). Few apps had undergone clinical validation. Only Apple App Store apps demonstrated significant correlations between MARS scores and app store star ratings. Conclusions: VA apps exhibited considerable heterogeneity in quality, functionality, and clinical use. Total mean MARS scores were similar between the Google Play Store and the Apple App Store, suggesting that neither platform consistently offers superior app quality. While many apps are technically sound, low subjective-quality scores and a lack of clinical validation limit their current use in professional practice. These findings underscore the need for more rigorous app development and validation standards to improve their relevance and reliability in teleophthalmology.